AstraZeneca PLC Stock Performance
AstraZeneca PLC has demonstrated strong momentum across multiple timeframes, with shares trading at $178.76. Per SID market data, AZN has gained 11.17% over the past month and 10.5% over the trailing three months, while the one-year return stands at an impressive 105.7%. The stock currently trades above its 50-day moving average of $169.68, reflecting sustained near-term bullish momentum, though it remains slightly below the 200-day moving average of $180.12. The 14-day relative strength index reads 66.9, indicating the stock is approaching overbought territory but has not yet crossed the conventional threshold. AZN's beta of 0.168, according to Massive/Polygon data, underscores its notably low correlation with broader market movements, characteristic of large-cap pharmaceutical names. Average daily trading volume stands at approximately 5.47 million shares, supporting consistent liquidity for institutional participants navigating this $279.9 billion market capitalization security.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC trades at a price-to-earnings ratio of 33.06, representing a premium valuation relative to the broader Healthcare sector, per SID market data. The PEG ratio stands at 4.53, suggesting the current earnings multiple substantially exceeds the company's projected growth rate, which may reflect the market pricing in long-term pipeline optionality. The price-to-book ratio of 6.24 further indicates investors are assigning significant value to intangible assets, including AstraZeneca's oncology and rare disease portfolios. According to SEC filings, the company offers a dividend yield of approximately 1.56%, providing a modest income component for shareholders. With a market capitalization of approximately $279.9 billion, AZN ranks among the largest global pharmaceutical companies. These valuation metrics collectively position AstraZeneca at a growth-oriented premium, reflecting elevated investor expectations for sustained revenue expansion from its diversified therapeutic pipeline and recent commercial successes.
Smart Money Activity for AZN
AstraZeneca PLC registers a smart money score of 59, reflecting a neutral composite signal across key institutional and insider tracking metrics. According to 13F institutional filings, AZN receives a perfect institutional score of 25 out of 25, indicating robust accumulation and sustained positioning by major fund managers. In contrast, the dark pool activity score sits at just 9.0 out of 25, suggesting limited off-exchange block trading activity in recent periods. Per SEC Form 4 filings, three insider transactions have been recorded over the past 90 days, all of which were purchases with zero insider sales, yielding an insider score of 12.5 out of 25. This unanimously bullish insider buying pattern signals internal confidence in the company's forward trajectory. The congressional trading score stands at 12 out of 25, indicating moderate legislative interest. The divergence between strong institutional accumulation and subdued dark pool activity creates a mixed but cautiously constructive smart money profile for AZN, warranting continued monitoring of insider transaction patterns.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has delivered substantial earnings surprises in its most recent reported quarters, according to company earnings reports. In the latest reported period, AZN posted actual earnings per share of $2.79 against an analyst estimate of $1.44, representing a positive surprise of $1.35, or approximately 93.8%. The prior reported quarter showed similarly robust outperformance, with actual EPS of $2.63 versus the consensus estimate of $1.52, yielding a $1.11 positive surprise. These consecutive beats underscore the company's ability to exceed market expectations through accelerating revenue growth and operational leverage. Looking ahead, per analyst estimates, the upcoming quarter carries a consensus EPS estimate of $1.44, with a subsequent quarter estimate of $1.35. AstraZeneca's next earnings report is scheduled for July 28, 2026. The pattern of meaningful upside surprises positions AZN favorably heading into its forthcoming reporting cycle.
Wall Street Analyst Ratings for AZN
Wall Street analyst coverage of AstraZeneca PLC reflects a divided outlook, per SID consensus data and recent analyst reports. On July 13, 2026, Berenberg Bank reiterated a Buy rating on AZN, reinforcing its constructive thesis on the company's commercial and pipeline trajectory. Jefferies has also maintained a Buy rating, reiterating on both June 26 and June 9, 2026, signaling sustained conviction in AstraZeneca's growth profile. In contrast, Deutsche Bank has taken a bearish stance, reiterating a Sell rating on June 26 and June 11, 2026, representing the notable dissenting view among recent coverage updates. This creates a clear bifurcation among analysts, with two firms maintaining Buy ratings and one firm holding a Sell recommendation across the five most recent rating actions. The divergence highlights differing assessments of AstraZeneca's valuation sustainability at its current P/E of 33.06 relative to pipeline execution risks and competitive dynamics within the global pharmaceutical landscape.